The D647N mutation of FGFR1 induces ligand-independent receptor activation.


Journal

Biochimica et biophysica acta. General subjects
ISSN: 1872-8006
Titre abrégé: Biochim Biophys Acta Gen Subj
Pays: Netherlands
ID NLM: 101731726

Informations de publication

Date de publication:
12 2023
Historique:
received: 10 07 2023
revised: 11 09 2023
accepted: 28 09 2023
medline: 6 11 2023
pubmed: 2 10 2023
entrez: 1 10 2023
Statut: ppublish

Résumé

The activation loop (A-loop) of kinases, a key regulatory region, is recurrently mutated in several kinase proteins in cancer resulting in dysregulated kinase activity and response to kinase inhibitors. FGFR1 receptor tyrosine kinase represents an important oncogene and therapeutic target for solid and hematological tumors. Here we investigate the biochemical and molecular effects of D647N mutation lying in the A-loop of FGFR1. When expressed in normal and tumoral in vitro cell models, FGFR1

Identifiants

pubmed: 37778450
pii: S0304-4165(23)00168-X
doi: 10.1016/j.bbagen.2023.130470
pii:
doi:

Substances chimiques

Ligands 0
Receptor, Fibroblast Growth Factor, Type 1 EC 2.7.10.1
FGFR1 protein, human EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

130470

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Mitola Stefania and Michela Corsini reports financial support was provided by Italian Association for Cancer Research. Silvia Codenotti and Elisabetta Grillo reports financial support was provided by Umberto Veronesi Foundation.

Auteurs

Mattia Domenichini (M)

Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy.

Cosetta Ravelli (C)

Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy.

Michela Corsini (M)

Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy.

Silvia Codenotti (S)

Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy.

Elisa Moreschi (E)

Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy.

Anna Gogna (A)

Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy.

Davide Capoferri (D)

Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy.

Daniela Zizioli (D)

Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy.

Roberto Bresciani (R)

Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy; Highly Specialized Laboratory, Diagnostic Department, ASST Spedali Civili of Brescia, Brescia, Italy.

Elisabetta Grillo (E)

Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy. Electronic address: elisabetta.grillo@unibs.it.

Stefania Mitola (S)

Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy. Electronic address: stefania.mitola@unibs.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH